|
Genetic alteration of clear cell renal cell carcinoma: RNA sequencing technology |
|---|---|
| รหัสดีโอไอ | |
| Creator | Thitiilat Chiraunyanan, Budsaba Rerkamnuaychoke |
| Title | Genetic alteration of clear cell renal cell carcinoma: RNA sequencing technology |
| Contributor | Thitiilat Chiraunyanan, Budsaba Rerkamnuaychoke |
| Publisher | Genetics Society of Thailand |
| Publication Year | 2564 |
| Journal Title | Genomics and Genetics |
| Journal Vol. | 14 |
| Journal No. | 2 |
| Page no. | 25-36 |
| Keyword | clear cell renal cell carcinoma (ccRCC), RNA sequencing, mutation, evolution, prognosis, therapy |
| URL Website | https://li01.tci-thaijo.org/index.php/gst/issue/view/17171 |
| Website title | https://li01.tci-thaijo.org/index.php/gst/article/view/248537 |
| ISSN | 24655198 |
| Abstract | Clear cell renal cell carcinoma (ccRCC), the most common subtype of renal cell carcinomas, is associated with a wide range of clinical outcomes. After surgery, approximately one-third of localized ccRCCpatients relapse withpoor clinical outcomes. Molecular profiling provides the tumor genomic landscape, revealing novel insight into mechanism and therapeutic target for cancer. A literature review challenges the current knowledge of the molecular and genetic basis of ccRCC. Next generation sequencing indicates the most frequent ccRCC driver events including Hipple-Lindau tumor suppressor gene, histone-modifying gene, alteration in the SWI/SNF complex and the PI3K/AKT/mTOR pathway or driver somatic copy number alteration.Intratumor heterogenous landscape using the RNA sequencing technology can providemechanisms of biological and tumor behavior in ccRCC to discover denovodiagnostic biomarkers in the early stage and de novoprognostic biomarkers in the tumor stage. More researchis needed on clinical outcome to prognostic value therapeutic strategies as special subtypes for clinical decision-making. The specific molecular target can thereby be moved towards precision medicine. |
